Metabolic Predictors of Incident Coronary Heart Disease in Women

BACKGROUND:Although metabolomic profiling offers promise for the prediction of coronary heart disease (CHD), and metabolic risk factors are more strongly associated with CHD in women than men, limited data are available for women. METHODS:We applied a liquid chromatography–tandem mass spectrometry m...

Full description

Saved in:
Bibliographic Details
Published in:Circulation (New York, N.Y.) N.Y.), 2018-02, Vol.137 (8), p.841-853
Main Authors: Paynter, Nina P, Balasubramanian, Raji, Giulianini, Franco, Wang, Dong D, Tinker, Lesley F, Gopal, Shuba, Deik, Amy A, Bullock, Kevin, Pierce, Kerry A, Scott, Justin, Martínez-González, Miguel A, Estruch, Ramon, Manson, JoAnn E, Cook, Nancy R, Albert, Christine M, Clish, Clary B, Rexrode, Kathryn M
Format: Article
Language:English
Subjects:
Aged
Chromatography, Liquid
Coronary Disease - blood
Coronary Disease - epidemiology
Female
Humans
Incidence
Metabolomics
Middle Aged
Phosphatidylcholines - blood
Predictive Value of Tests
Risk Factors
Tandem Mass Spectrometry
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND:Although metabolomic profiling offers promise for the prediction of coronary heart disease (CHD), and metabolic risk factors are more strongly associated with CHD in women than men, limited data are available for women. METHODS:We applied a liquid chromatography–tandem mass spectrometry metabolomics platform to measure 371 metabolites in a discovery set of postmenopausal women (472 incident CHD cases, 472 controls) with validation in an independent set of postmenopausal women (312 incident CHD cases, 315 controls). RESULTS:Eight metabolites, primarily oxidized lipids, were significantly dysregulated in cases after the adjustment for matching and CHD risk factors in both the discovery and validation data sets. One oxidized phospholipid, C34:2 hydroxy-phosphatidylcholine, remained associated with CHD after further adjustment for other validated metabolites. Subjects with C34:2 hydroxy-phosphatidylcholine levels in the highest quartile had a 4.7-fold increase in CHD odds in comparison with the lowest quartile; C34:2 hydroxy-phosphatidylcholine also significantly improved the area under the curve (P
ISSN:0009-7322
1524-4539
DOI:10.1161/CIRCULATIONAHA.117.029468